I have posted this a few times and thought I would again considering the Amgen news. Just a quick comparison to show how ONCS continues to be severely undervalued and has the potential for substantial growth from its current pps. These are 3 acquisitions from the past few years.
$425MM in cash plus $575MM in payments for regulatory and sale milestones
1 drug in Phase 3 that was recruiting patients
1 drug under development in the UK
An operational manufacturing facility
Amgen-Micromet $1.16B in cash
1 drug under going multiple trials with no further progression than ongoing Phase 2s
Proprietary BiTE antibody technology for future research and potential milestone/royalty payments from licensing
Rights to one antibody in Phase 1
A site for R&D
$350MM in cash plus $195MM for milestones of the drug's successful development and approval, plus $380MM for milestones from drugs developed and approved from the platform
1 drug in Phase 1
Proprietary Avilomics Platform for discovery and development
What does OncoSec have to offer:
Ready for market in Europe
CE Mark for Europe,
Patent for China for method of use and device.
Patent Protection through 2024
Phase 2 Malignant Melanoma, planned Phase 2B combo w/ anti-PD-1(potential BD and AA)
Phase 2 Merkel Cell Carcinoma (potential OD/OA)
Phase 2 Cutaneous T-cell Lymphoma
Producing outstanding data thus far, in fact leading the way with their results
The SRA with Old Dominion
Soon to be new clinical trial for ImmunoPulse w/anti-PD-1
Expected Partnership announcement.
Cash on hand to run through 2015
Along with some other "assets" OncoSec acquired from INO that have yet to be disclosed publicly.
ONCS is severely undervalued with its current MC of $175MM and if things line up as they have the potential to, then ONCS shareholders will be rewarded several times over.
Sentiment: Strong Buy
Definitely puts things in perspective.. add the fact that biotech investor's are exiting overpriced bio's and looking for undervalued bio's with catalyst on the horizon and you have the makings for a very good year to say the least.. long term looks even better
Sentiment: Strong Buy
First of all I enjoy your posts. This may be my first post on this board but I'm in since $.358 and hoping for the next AMGN, which all evidence points towards ONCS MAY BE !!!!! I Like ONCS chances ! I Like OHRP chances !